logo

AKTX

Akari Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.41 / 10
Netural

The company exhibits challenging fundamental metrics (3.4/10). Strengths are observed in Interest coverage ratio (EBIT / Interest expense) (%) and Asset-MV, with caution warranted for PB-ROE and Days sales outstanding. Overall, the fundamental outlook is negative.

Fundamental(3.41)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight18.84%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.61%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.07%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight15.04%
1M Return8.45%
PB-ROE
Value-0.33
Score1/3
Weight18.29%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.37%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight14.77%
1M Return8.41%
Is AKTX fundamentally strong?
  • AKTX scores 3.41/10 on fundamentals and holds a Fair valuation at present. Backed by its -53.43% ROE, 0.00% net margin, -0.68 P/E ratio, 0.47 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.